Study of GNS561 in Patients With Liver Cancer

  • STATUS
    Recruiting
  • End date
    Jan 15, 2022
  • participants needed
    50
  • sponsor
    Genoscience Pharma
Updated on 7 August 2021
ct scan
platelet count
liver cancer
renal function
cancer
hepatitis
antiviral therapy
kidney function tests
neutrophil count
liver metastases
antiviral drugs
hepatoma
icca
contraceptive foam

Summary

This is a first in human, open-label dose escalation study to investigate the safety, tolerability and pharmacokinetics of GNS561 in patients Primary and Secondary liver cancer

Description

This is a multicenter, open-label, uncontrolled, repeat-dose Phase 1/2a study designed to evaluate the safety profile and to determine the recommended Phase 2 dose of GNS561 in patients with advanced primary and secondary liver cancer. This study will enroll approximately 50 patients and consists of 2 parts: Phase 1(dose escalation) and Phase 2 (expansion). All patients will be treated until the occurrence of an unacceptable toxicity, disease progression, or withdrawal of consent. In this study a treatment cycle is defined as 4 weeks (28 days). Patients are to take their assigned dose of GNS561, in the Morning and in the evening at the same time everyday, following a meal.

Details
Condition Adenocarcinoma, HEPATIC NEOPLASM, HEPATOCELLULAR CARCINOMA, Cholangiocarcinoma, Intrahepatic, Liver Cancer, Malignant Adenoma, Cholangiocarcinoma, Intrahepatic, Cholangiocarcinoma, Intrahepatic, liver cell carcinoma, Cholangiocarcinoma, Intrahepatic, Cholangiocarcinoma, Intrahepatic, Cholangiocarcinoma, Intrahepatic, Cholangiocarcinoma, Intrahepatic
Treatment GNS561
Clinical Study IdentifierNCT03316222
SponsorGenoscience Pharma
Last Modified on7 August 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Males or females 18 years of age
Histologically confirmed and documented locally advanced or metastatic HCC that is deemed not appropriate for curative therapy and Histologically confirmed and documented locally advanced or metastatic iCCA
Liver tumor burden< 50% of the liver (per Investigator judgment)
Antiviral therapy required in hepatitis B virus patients (Hepatitis B antigen positive)
Willing to have liver biopsy at the beginning of cycle 2 (Day 1)
Presence of a measurable tumor per RECIST v1.1 criteria
Eastern Cooperative Oncology Group (ECOG) performance status 1
Life expectancy 12 weeks
Adequate hematologic function prior to the first dose of GNS561, defined as
Absolute neutrophils count 1500 cells/L
Hemoglobin 10 g/dL with no transfusion within 4 weeks prior to first planned dose of GNS561
Platelet count > 50,000/L with no transfusion within 2 weeks prior to first planned dose of GNS561
Adequate renal function prior to first dose, defined as
Serum creatinine < 1.5 ULN
Creatinine clearance 50 mL/min/m2 (by Cockroft-Gault equation of 24-hour urine) if creatinine 1.5 X ULN
Adequate hepatic function prior to first dose, defined as AST/ALT 5 X ULN
Women patients of childbearing potential must have a negative serum/urine pregnancy test at screening and baseline, and be willing to use a medically acceptable form, as judged by Investigator and Sponsor, of contraception (e.g., hormonal birth control, intrauterine device [IUD], or barrier method [male condom, female condom, diaphragm]), plus a spermicidal agent [contraceptive foam, jelly, or cream]) or abstinence or bilateral occlusion or whose partner had a vasectomy at least 2 years before screening. The patient should be advised to continue the contraception for at least 6 months following the completion of dosing. Women with cessation for > 24 months of previously occurring menses, or women of any age who have had a hysterectomy, or have had both ovaries removed will be considered to be of non-childbearing potential
Male patients of reproductive potential must be willing to use one acceptable method of contraception, as judged by Investigator and Sponsor, as described in Criteria 12 and/or to refrain from donating sperm from the time of screening through at least 6 months following the completion of dose administration
Amenable to computed tomography (CT) with 3 or 4 phase liver or magnetic resonance imaging (MRI) of abdomen and pelvis, and CT of chest, or MRI of whole body, for initial tumor size measurements and subsequent follow-up
Absence of other clinically relevant abnormalities for screening laboratory test results as judged by the Investigator and Sponsor
Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
Be willing to abstain from alcohol from signing of informed consent through Week 5 (completion of PK sampling at the beginning of Cycle 2)
Able to understand and provide written informed consent

Exclusion Criteria

Pregnant or breast-feeding mothers
Any known history of encephalopathy
Known esophageal varices with recent history of bleeding (within previous 2 months)
Clinically significant ascites or paracentesis
Known untreated or symptomatic brain metastases
Presence of residual toxicities of Grade 2 after prior antitumor therapy 4 weeks prior to first dose. Grade 1 toxicities related to previous treatments are acceptable at the time of the first planned dose of GNS561, as well as any alopecia
Chronic treatment with immunosuppressive agents (like steroids) 6 weeks prior to first planned dose of GNS561
Major surgical procedures, open biopsy or significant traumatic injury 4 weeks prior to first dose of GNS561 or anticipation of major surgical procedure during the course of the trial, minor surgical procedures 1 week of first planned dose
Any clinically significant cardiovascular condition as judged by the Investigator
Severe or uncontrolled renal condition
Untreated chronic hepatitis B
Known history of immunodeficiency diseases (e.g., active HIV)
Use of any prohibited concomitant medications within 14 days of the Baseline/Day 1 visit
Known current alcohol (> 20g/ Day in women and > 30g/ Day in men) or substance abuse
Malabsorption issues (e.g., gastric bypass or gastrectomy patients)
Participation in any investigational clinical investigation 4 weeks prior to first planned dose of GNS561 or longer if required by local regulations, and for any other limitation of participation based on local regulations
Known clinically significant or life threatening organ or systemic disease such that in the opinion of the Investigator, the significance of the disease will compromise the patient's participation in the trial
Is a participant or plans to participate in another investigational clinical study, while taking part in this study
Known intolerance or hypersensitivity to the active ingredient or to one of the components of the study drug
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note